Clinical Trial Update: TocilizuMab discontinuAtion in GIant Cell Arteritis [Phase 3]

View source ↗

Summary

A Phase 3 trial of tocilizumab for giant cell arteritis has been discontinued.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Giant Cell Arteritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING